Antibiotic drug interactions fall into two broad categories: pharmacokinetic interactions, in which one drug alters the absorption, distribution, metabolism, or elimination of another, and pharmacodynamic interactions, in which two drugs act on the same physiological target or toxicity pathway to produce additive, synergistic, or antagonistic effects. Clinically significant interactions are most common with agents that are substrates, inhibitors, or inducers of cytochrome P450 (CYP) enzymes, and with agents that prolong the ventricular repolarization interval on the electrocardiogram — measured as the QT interval (QT) and corrected for heart rate as the QTc — through blockade of the hERG potassium channel.1
Macrolide antibiotics are among the most clinically important CYP inhibitors in the antibiotic class. Erythromycin and clarithromycin are potent inhibitors of CYP3A4 (cytochrome P450 isoenzyme 3A4), the isoenzyme responsible for metabolizing a large proportion of commonly prescribed drugs including statins (simvastatin, lovastatin), calcineurin inhibitors (tacrolimus, cyclosporine), some calcium channel blockers (felodipine, amlodipine), benzodiazepines (midazolam, triazolam), and warfarin.1 Co-administration of erythromycin or clarithromycin with simvastatin or lovastatin is contraindicated due to the risk of severe rhabdomyolysis from markedly elevated statin concentrations. Azithromycin is a much weaker CYP3A4 inhibitor and carries a substantially lower burden of metabolic drug interactions, which partly explains its clinical dominance over erythromycin and clarithromycin for community-acquired respiratory tract infections. Telithromycin, a ketolide antibiotic, is a particularly potent CYP3A4 inhibitor and carries a black box warning for liver toxicity in addition to its interaction burden, limiting its clinical use.
Fluoroquinolones interact with several important drug classes through multiple mechanisms. All fluoroquinolones chelate divalent and trivalent cations (calcium, magnesium, iron, zinc, aluminum), which dramatically reduces oral absorption when they are co-administered with antacids, calcium supplements, iron preparations, sucralfate, or dairy products containing calcium; the fluoroquinolone must be taken at least two hours before or six hours after such agents.2 Ciprofloxacin is a significant inhibitor of CYP1A2 (cytochrome P450 isoenzyme 1A2) and moderately inhibits CYP3A4; it raises theophylline concentrations by approximately 70 percent through CYP1A2 inhibition, making the ciprofloxacin-theophylline combination potentially dangerous if theophylline levels are not monitored. Fluoroquinolones prolong the QTc interval through hERG channel inhibition; this effect is most pronounced with moxifloxacin (which is not renally eliminated and thus achieves high plasma concentrations), intermediate with levofloxacin, and minimal with ciprofloxacin. Co-administration of fluoroquinolones with other QTc-prolonging agents (sodium channel-blocking antiarrhythmics such as quinidine, procainamide, and disopyramide; potassium channel-blocking antiarrhythmics such as amiodarone and sotalol; antipsychotics; tricyclic antidepressants; azole antifungals) requires electrocardiographic monitoring and should be avoided when alternatives exist.
Rifampicin (rifampin) is one of the most potent inducers of CYP3A4, CYP2C9 (cytochrome P450 isoenzyme 2C9), CYP2C19 (isoenzyme 2C19), and multiple other metabolic pathways in clinical medicine, and drug interactions with rifampicin-containing regimens are pervasive and clinically critical.3 Rifampicin dramatically reduces plasma concentrations of drugs metabolized by these enzymes, including oral contraceptives (requiring additional barrier contraception during and for one month after rifampicin therapy), warfarin (requiring substantially increased warfarin doses to maintain a therapeutic international normalized ratio [INR]), human immunodeficiency virus (HIV) antiretrovirals (especially protease inhibitors and non-nucleoside reverse transcriptase inhibitors), calcineurin inhibitors, methadone, corticosteroids, and many antifungals. The induction effect takes approximately one to two weeks to develop fully and similarly one to two weeks to resolve after discontinuation, during which time target drug concentrations may be sub- or supra-therapeutic, requiring close monitoring of drug levels and clinical effects through both the initiation and cessation periods.
Several antibiotic drug interactions operate through pharmacodynamic mechanisms independent of enzyme induction or inhibition. Aminoglycosides and loop diuretics (furosemide, ethacrynic acid) both cause ototoxicity through damage to cochlear hair cells; their combination produces synergistic ototoxicity and should be avoided whenever possible, or used only with audiometric monitoring when unavoidable. The combination of vancomycin with piperacillin-tazobactam has been associated with a significantly increased incidence of acute kidney injury (AKI) compared to vancomycin alone in multiple retrospective and prospective studies, though the mechanism remains debated (proposed mechanisms include competitive inhibition of tubular secretion of vancomycin metabolites and direct tubular toxicity from piperacillin-tazobactam).4 Tetracyclines and penicillins can exhibit pharmacodynamic antagonism: penicillins are bactericidal agents that require active cell wall synthesis in rapidly dividing bacteria to exert their killing effect, while tetracyclines are bacteriostatic agents that arrest protein synthesis and reduce the rate of bacterial growth; in vitro data and some clinical observations suggest that concurrent use can attenuate the bactericidal effect of penicillins, particularly in conditions such as bacterial meningitis where bactericidal activity is clinically critical.
Linezolid carries a unique and potentially life-threatening interaction with serotonergic agents. Linezolid is a non-selective, reversible inhibitor of monoamine oxidase (MAO), and its combination with serotonin-reuptake inhibitors (selective serotonin reuptake inhibitors, or SSRIs; serotonin-norepinephrine reuptake inhibitors, or SNRIs), tricyclic antidepressants, triptans, or opioids with serotonergic properties (tramadol, meperidine, fentanyl) can precipitate serotonin syndrome, manifesting as agitation, hyperthermia, myoclonus, tachycardia, and potentially life-threatening autonomic instability.5 Current prescribing information recommends avoiding linezolid in patients taking serotonergic drugs unless the benefit clearly outweighs the risk, and clinicians should be prepared to discontinue all serotonergic agents before initiating linezolid when the clinical situation permits. Tedizolid, a newer oxazolidinone, has weaker MAO inhibitory activity and a potentially lower risk of serotonin syndrome, though clinical data are more limited.
Before prescribing moxifloxacin, azithromycin, clarithromycin, or any other QTc-prolonging antibiotic, check: (1) baseline QTc on electrocardiogram (ECG) — avoid if QTc exceeds 500 ms or exceeds 60 ms above the patient's baseline; (2) concurrent QTc-prolonging medications; (3) electrolyte status — hypokalemia and hypomagnesemia lower the threshold for torsades de pointes; (4) underlying cardiac disease — congenital long QT syndrome, recent myocardial infarction, and heart failure are major additional risk factors. Resources such as crediblemeds.org provide regularly updated risk stratification lists for drug-induced QTc prolongation.
Antibiotic adverse effects span from minor nuisances that do not require discontinuation to rare but life-threatening reactions that demand immediate management. Class-specific toxicity profiles are determined by the mechanism of action, pharmacokinetic distribution, and off-target binding of each drug family. Recognizing class-specific adverse effect signatures enables earlier attribution and more appropriate management.6
Beta-lactams are generally the safest antibiotic class in terms of direct organ toxicity, but hypersensitivity reactions represent their most clinically important adverse effect category. Immediate hypersensitivity reactions (urticaria, angioedema, bronchospasm, anaphylaxis) are IgE-mediated and occur in approximately 1 to 5 per 10,000 courses of penicillin therapy.6 Penicillin skin testing is the gold standard for evaluating IgE-mediated penicillin allergy; patients who test negative can receive penicillins with the same risk as the general population. The historical cross-reactivity rate between penicillins and cephalosporins, estimated at approximately 1 to 2 percent based on modern data (far lower than the frequently cited but outdated 10 percent figure), is attributable to shared side-chain epitopes rather than the beta-lactam ring itself, meaning that cross-reactivity depends on structural similarity of the side chains rather than drug class membership. Carbapenems have a very low cross-reactivity rate with penicillins in skin-test-positive patients (~1 percent) and are generally safe to use in most penicillin-allergic patients. Direct Coombs-positive hemolytic anemia and neutropenia occur rarely with prolonged high-dose beta-lactam therapy, particularly with nafcillin and high-dose piperacillin-tazobactam.
Aminoglycosides carry two dose-dependent, cumulative toxicities that require active monitoring: nephrotoxicity and ototoxicity. Nephrotoxicity results from accumulation of drug in the proximal tubular cells of the renal cortex, where aminoglycosides bind to negatively charged phospholipids in the brush border membrane and undergo endocytosis; intracellular accumulation disrupts lysosomal function and generates reactive oxygen species (ROS), ultimately causing tubular cell necrosis.7 Risk factors include pre-existing renal impairment, volume depletion, concurrent nephrotoxins (vancomycin, non-steroidal anti-inflammatory drugs, contrast agents), prolonged duration, and higher total daily doses. Extended-interval (once-daily) aminoglycoside dosing, which exploits the concentration-dependent bactericidal activity and post-antibiotic effect of aminoglycosides, is now preferred for most indications because the prolonged drug-free interval allows tubular cells to clear the drug before the next dose, reducing cumulative cortical accumulation compared to traditional multiple-daily dosing. Ototoxicity (both cochlear causing sensorineural hearing loss, and vestibular causing vertigo and ataxia) is also cumulative and frequently irreversible; audiometric monitoring is recommended for patients receiving aminoglycosides for more than 14 days.
Fluoroquinolones carry a United States Food and Drug Administration (FDA) black box warning for tendinopathy, tendon rupture, peripheral neuropathy, and central nervous system (CNS) effects, and the FDA 2016 safety communication recommends reserving fluoroquinolones for serious infections when no safer alternative exists.2 Tendinopathy and tendon rupture (most commonly the Achilles tendon, but also involving the rotator cuff, quadriceps, and other tendons) are mediated by fluoroquinolone-induced disruption of tendon collagen synthesis and matrix metalloproteinase activation; the risk is substantially elevated in patients aged over 60 years, patients receiving concurrent corticosteroids, patients with kidney disease, and patients with prior tendinopathy. Peripheral neuropathy from fluoroquinolones may be permanent and includes sensory (paresthesias, dysesthesias) and motor components; it can occur within days of initiation. CNS effects include seizures (particularly with theophylline co-administration or in patients with renal failure using renally cleared fluoroquinolones), insomnia, anxiety, and hallucinations, which are most common with ciprofloxacin. The FDA added aortic aneurysm and dissection as a contraindication in high-risk patients (those with existing aneurysm, hypertension, or genetic conditions predisposing to aortic disease) in 2018.
Glycopeptides and lipopeptides share nephrotoxicity as a primary concern. Vancomycin nephrotoxicity, now understood to be mediated primarily by oxidative stress in proximal tubular cells at high drug exposures, is monitored through area-under-the-curve-to-MIC ratio (AUC/MIC)-guided dosing using Bayesian methods, which has replaced trough-only monitoring following the 2020 joint guidelines from the American Society of Health-System Pharmacists (ASHP), the Infectious Diseases Society of America (IDSA), and the Society of Infectious Diseases Pharmacists (SIDP).8 The target AUC/MIC of 400 to 600 mg·h/L (for MIC of 1 mg/L) is associated with both therapeutic efficacy and acceptable nephrotoxicity risk. Red man syndrome (RMS), a non-IgE-mediated infusion reaction causing flushing, erythema, and pruritus of the head, neck, and upper torso, results from direct mast cell degranulation by vancomycin and is prevented by infusing the drug over at least 60 minutes; antihistamine premedication can further reduce RMS risk. Daptomycin causes skeletal muscle toxicity (myopathy) through a mechanism involving disruption of cell membrane function in muscle cells; creatine phosphokinase (CPK) levels must be monitored weekly during daptomycin therapy, and the drug should be discontinued if CPK rises more than 5 times the upper limit of normal in symptomatic patients or more than 10 times with or without symptoms. Daptomycin must never be used for pneumonia due to inactivation by pulmonary surfactant.
Tetracyclines cause photosensitivity through a phototoxic (non-immunological) mechanism in which the drug absorbs ultraviolet (UV) radiation and undergoes photo-excitation, generating free radicals that damage exposed skin cells; patients must be counseled to use sunscreen and minimize sun exposure during therapy.9 Tetracyclines chelate calcium in developing bone and teeth, producing permanent yellow-gray staining and enamel hypoplasia in children under 8 years of age and in fetuses when administered to pregnant women after the first trimester; this accounts for their contraindication in young children and pregnancy (see Section 4). Doxycycline causes esophageal ulceration if tablets are swallowed without adequate water and in the supine position; patients must remain upright for at least 30 minutes after dosing. Tigecycline, a glycylcycline tetracycline derivative, carries an FDA black box warning for increased all-cause mortality compared to other antibiotics in clinical trials of serious infections, limiting its use to situations where alternatives are not available.
The FDA black box warning for fluoroquinolones covers five categories: (1) tendinitis and tendon rupture; (2) peripheral neuropathy (may be permanent); (3) CNS effects (psychosis, increased intracranial pressure, seizures); (4) exacerbation of myasthenia gravis (contraindicated in known MG); (5) aortic aneurysm and dissection (high-risk patients). These risks do not negate fluoroquinolone use in serious infections where no alternative exists but mandate informed prescribing, patient counseling, and prompt drug discontinuation at first signs of any of these adverse effects.
Approximately 75 percent of antibiotic dose adjustments in clinical practice are driven by renal impairment, because most antibiotics and their active metabolites are eliminated primarily through renal filtration or secretion. Failure to adjust doses in renal impairment risks drug accumulation, toxicity, and in some cases, organ damage that is itself a consequence of the antibiotic being used to treat the infection.10
Creatinine clearance (CrCl), estimated using the Cockcroft-Gault equation with actual body weight (or ideal body weight in obese patients), remains the standard pharmacokinetic variable used for renal dosing adjustments in antibiotic prescribing, despite the increasing availability of chronic kidney disease (CKD) staging by estimated glomerular filtration rate (eGFR) using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.10 The Cockcroft-Gault CrCl is preferred for antibiotic dosing because it was the metric used in original pharmacokinetic studies of most established agents and because it incorporates body weight (relevant to drug volume of distribution) in addition to serum creatinine. In acutely ill patients with acute kidney injury (AKI), serum creatinine may lag behind the actual glomerular filtration rate (GFR) by 24 to 48 hours during the initial phase of injury; urine output trends and dynamic creatinine kinetics can provide additional context. Augmented renal clearance (ARC), defined as CrCl exceeding 130 mL/min and found in young, severely ill patients with high cardiac output states (sepsis, trauma, burns), poses the opposite problem: standard doses may produce subtherapeutic concentrations, requiring dose escalation of renally cleared antibiotics such as beta-lactams and aminoglycosides.
Beta-lactam antibiotics require dose adjustment at varying CrCl thresholds depending on the specific agent and the degree of renal dependence. Penicillins are primarily renally eliminated; ampicillin, piperacillin-tazobactam, and oxacillin doses are reduced when CrCl falls below 10 to 30 mL/min. Cephalosporins vary by generation: cefazolin requires adjustment only at CrCl below 35 mL/min, while ceftriaxone is primarily biliary eliminated and requires no renal adjustment (making it useful in severe renal failure).10 Carbapenems require adjustment as follows: imipenem-cilastatin is reduced when CrCl falls below 70 mL/min (to prevent seizures from drug accumulation); meropenem is adjusted below 26 mL/min; ertapenem below 30 mL/min. Aztreonam requires dose reduction below CrCl 30 mL/min. For time-dependent beta-lactams (where efficacy correlates with the percentage of time that free drug concentrations exceed the minimum inhibitory concentration (MIC), extended or continuous infusion strategies can be used in severe infections even with dose reduction in renal impairment, maintaining adequate pharmacodynamic target attainment while limiting peak concentrations.
Aminoglycosides require the most careful renal dose adjustment of any antibiotic class given their narrow therapeutic index and direct nephrotoxicity. For extended-interval (once-daily) dosing, the Hartford nomogram or equivalent tool is used in patients with CrCl exceeding 20 to 40 mL/min; in patients with CrCl below this threshold, multiple-daily dosing with therapeutic drug monitoring (TDM) of peak (30 minutes after infusion end) and trough (30 minutes before next dose) concentrations is preferred.7 Target peaks for gentamicin and tobramycin are 5 to 10 mg/L for gram-negative infections and 15 to 20 mg/L for pneumonia or endocarditis; troughs must remain below 2 mg/L (ideally below 1 mg/L) to minimize nephrotoxicity risk. Amikacin targets are 20 to 35 mg/L peak and below 5 mg/L trough. In patients on continuous renal replacement therapy (CRRT) or intermittent hemodialysis, aminoglycosides are significantly cleared and supplemental doses are required post-dialysis; vancomycin is similarly dialyzable and requires post-dialysis dosing. Vancomycin area-under-the-curve-to-MIC ratio (AUC/MIC)-guided dosing requires initial loading doses independent of renal function (given that the AUC/MIC ratio target requires a minimum initial exposure), followed by maintenance doses adjusted downward in proportion to CrCl reduction.
Hepatically metabolized antibiotics require dose adjustment primarily in severe hepatic impairment (Child-Pugh class C cirrhosis), though the relationship between liver function tests and hepatic drug-metabolizing capacity is complex and not directly proportional. Metronidazole is extensively hepatically metabolized, and its half-life may extend significantly in severe hepatic failure, requiring dose reduction or interval extension and avoiding prolonged courses.11 Clindamycin undergoes extensive CYP3A4 (cytochrome P450 3A4)-mediated hepatic metabolism and requires dose reduction in severe hepatic impairment. Chloramphenicol, though rarely used in the United States, is metabolized hepatically by glucuronosyltransferases; accumulation in hepatic failure and in neonates (who have immature glucuronidation) causes gray baby syndrome (cardiovascular collapse) through mitochondrial toxicity. Macrolides, particularly erythromycin, require caution in significant hepatic disease due to the risk of cholestatic hepatitis and impaired metabolism; azithromycin distributes extensively to the liver and is excreted primarily in bile, requiring caution in severe liver disease. Rifampicin requires dose reduction in hepatic impairment and is itself hepatotoxic; liver function tests must be monitored during rifampicin-based regimens for tuberculosis and other chronic infections.
Ceftriaxone is unique among the cephalosporins in being primarily eliminated by biliary excretion (approximately 40 to 60 percent) rather than renal filtration. No dose adjustment is required for any degree of renal impairment, including dialysis dependence, making it a pharmacokinetically convenient choice when a third-generation cephalosporin is needed in patients with severe kidney disease. However, ceftriaxone is contraindicated in neonates with hyperbilirubinemia (competes with bilirubin for albumin binding), and its biliary elimination predisposes to biliary sludge and cholelithiasis with prolonged use, requiring monitoring in patients on extended ceftriaxone therapy.
Antibiotic selection in pregnancy requires balancing the risk of untreated infection (which may pose a greater risk to the mother and fetus than the drug) against the teratogenic or fetotoxic potential of the antibiotic. Similarly, antibiotic prescribing in neonates and infants must account for the dramatic ontogenic changes in pharmacokinetic parameters that occur during the first weeks and months of life and that differ in essential ways from adult drug behavior.12
Beta-lactam antibiotics are the safest antibiotic class in pregnancy and are the agents of choice for most bacterial infections occurring during pregnancy, including group B streptococcal (GBS) prophylaxis in labor, urinary tract infections (UTIs), and community-acquired pneumonia (CAP) in pregnant patients.12 Penicillins, cephalosporins, and carbapenems cross the placenta but have not been associated with fetal harm in animal studies or large human epidemiological studies. Aztreonam is also considered safe in pregnancy. Erythromycin (but not erythromycin estolate, which causes cholestatic hepatitis) and azithromycin are considered acceptable for penicillin-allergic pregnant patients. Nitrofurantoin is used for uncomplicated lower urinary tract infection (UTI) in pregnancy but is contraindicated in the third trimester (particularly at term) due to the risk of neonatal hemolytic anemia in glucose-6-phosphate dehydrogenase (G6PD)-deficient neonates and theoretical concern for pulmonary toxicity in near-term infants.15 Trimethoprim-sulfamethoxazole (TMP-SMX) is avoided in the first trimester (trimethoprim inhibits dihydrofolate reductase and may contribute to folate deficiency and neural tube defects) and at term (sulfonamides displace bilirubin from albumin, risking neonatal kernicterus).
Tetracyclines are contraindicated throughout pregnancy due to chelation of calcium in developing fetal bones and teeth, causing permanent enamel hypoplasia and gray-yellow discoloration; this risk is most pronounced after the first trimester when calcification of primary teeth begins.9 Doxycycline and minocycline share this contraindication. Fluoroquinolones are generally avoided in pregnancy due to demonstrated arthropathy in immature animals (though the clinical significance in humans is debated); they should not be used unless no safer alternative exists. Aminoglycosides cross the placenta and accumulate in fetal renal tissue and perilymph; while streptomycin has documented cases of fetal sensorineural hearing loss, the evidence for ototoxicity from gentamicin, tobramycin, and amikacin in utero is less certain but still warrants avoidance unless maternal infection risk outweighs fetal risk. Metronidazole was historically avoided in the first trimester due to concerns from animal mutagenicity data, though large human epidemiological studies have not confirmed teratogenicity; current guidelines generally consider it acceptable after the first trimester and for single-dose treatment of trichomoniasis at any gestational age when clinically necessary.
Antibiotic use during lactation requires consideration of the infant dose through breast milk, calculated as the relative infant dose (RID), which is the infant's weight-adjusted dose as a percentage of the maternal weight-adjusted dose.13 An RID below 10 percent is generally considered acceptable for most drugs. Beta-lactams achieve low milk concentrations and very low RID values (typically below 1 percent), making them compatible with breastfeeding. Azithromycin achieves slightly higher milk concentrations but is also considered compatible. Tetracyclines are excreted into milk but are extensively chelated by calcium in milk, which reduces absorption from the infant's gut; short courses (less than three weeks) are generally considered acceptable during breastfeeding, though prolonged use is avoided. Fluoroquinolones achieve variable milk concentrations; ciprofloxacin milk concentrations are relatively low and most authorities consider brief courses compatible with breastfeeding, while moxifloxacin data are more limited. Metronidazole is excreted into milk and can produce a bitter taste that may cause infant feeding refusal; pumping and discarding milk for 12 to 24 hours after a single high dose (2 g) is sometimes recommended, though the RID from standard dosing is generally below 10 percent and many authorities consider standard dosing compatible with breastfeeding.
Pediatric antibiotic pharmacokinetics differ substantially from adult pharmacokinetics due to ontogenic changes in body composition, plasma protein binding, renal function, and hepatic enzyme maturation.14 Neonates (birth to 28 days) have a larger volume of distribution for water-soluble drugs (due to higher total body water and lower body fat), reduced plasma protein binding (due to lower albumin concentrations and competition from bilirubin and fatty acids), immature renal filtration and tubular secretion (glomerular filtration rate reaches adult values by 6 to 12 months), and immature hepatic cytochrome P450 (CYP) enzyme activity; specifically, CYP3A4 (the 3A4 isoenzyme) operates at approximately 30 percent of adult activity at birth and reaches adult levels by 6 to 12 months. As a result, aminoglycoside dosing intervals in neonates are substantially extended compared to older children, and the once-daily aminoglycoside approach used in adults must be replaced by age- and weight-specific extended-interval protocols. Chloramphenicol causes gray baby syndrome in neonates through accumulation of unconjugated chloramphenicol due to immature glucuronidation; plasma concentration monitoring is mandatory if chloramphenicol must be used in this age group. Fluoroquinolones are generally restricted to carefully selected pediatric indications (complicated UTIs caused by multidrug-resistant (MDR) organisms, pulmonary exacerbations in cystic fibrosis patients, anthrax exposure) due to concerns about arthropathy; ciprofloxacin is the most commonly used fluoroquinolone in pediatrics when indicated.
Weight-based dosing (mg/kg) is standard for antibiotics in children under 40 to 50 kg, beyond which adult doses are typically applied. Maximum doses based on adult standard dosing must be applied to prevent inadvertent overdosing of larger children or adolescents. Renal dosing adjustments in pediatrics follow the same CrCl thresholds as adults but require age-specific estimation of CrCl using the Schwartz equation (which incorporates height in addition to serum creatinine) rather than the Cockcroft-Gault equation.14 Therapeutic drug monitoring is particularly important in neonates and severely ill children, where pharmacokinetic variability is greatest and standard weight-based dosing may produce widely variable drug exposures.
Generally safe throughout pregnancy: penicillins, cephalosporins, carbapenems, aztreonam, erythromycin (base, not estolate), azithromycin, clindamycin (for specific indications), nitrofurantoin (avoid at term). Avoid in first trimester: TMP-SMX (folate antagonism), metronidazole (though evidence for harm is weak). Avoid at term: TMP-SMX (neonatal kernicterus risk), nitrofurantoin (neonatal hemolytic anemia risk). Contraindicated throughout pregnancy: tetracyclines (bone/tooth dysplasia), fluoroquinolones (arthropathy risk), aminoglycosides (ototoxicity risk, particularly streptomycin). Vancomycin, linezolid, and daptomycin are used when necessary with appropriate monitoring; limited human safety data exist for many newer agents.
Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 2000;38(1):41–57.
doi:10.2165/00003088-200038010-00003FDA Drug Safety Communication. FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections. US Food and Drug Administration. 2016. Updated 2018.
fda.gov/drugs/drug-safety-and-availabilityNiemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet. 2003;42(9):819–850.
doi:10.2165/00003088-200342090-00003Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis. 2009;49(4):507–514.
doi:10.1086/600884Wagen AZ, Dagan R, Solt I, et al. Serotonin syndrome associated with linezolid: a clinical review. J Antimicrob Chemother. 2016;71(3):566–571.
doi:10.1093/jac/dkv371Macy E, Romano A, Khan D. Practical management of antibiotic hypersensitivity in 2017. J Allergy Clin Immunol Pract. 2017;5(3):577–586.
doi:10.1016/j.jaip.2017.02.014Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2020;77(11):835–864.
doi:10.1093/ajhp/zxaa036Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review. Clin Infect Dis. 2020;71(6):1361–1364.
doi:10.1093/cid/ciaa303Cunha BA. Minocycline and doxycycline: current and emerging clinical indications. Expert Rev Anti Infect Ther. 2012;10(6):731–742.
doi:10.1586/eri.12.49Aronoff GR, Bennett WM, Berns JS, et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children. 5th ed. Philadelphia: American College of Physicians; 2007.
doi:10.7326/0003-4819-147-3-200708070-00222Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64(12):1147–1161.
doi:10.1007/s00228-008-0553-zBookstaver PB, Bland CM, Griffin B, Stover KR, Eiland LS, McLaughlin M. A review of antibiotic use in pregnancy. Pharmacotherapy. 2015;35(11):1052–1062.
doi:10.1002/phar.1649Hale TW. Medications and mothers milk. Planta Med. 2012;78(18):1837–1846.
doi:10.1055/s-0032-1328062Smits A, Kulo A, de Hoon JN, Allegaert K. Pharmacokinetics of drugs in neonates: pattern recognition beyond single-drug studies. Curr Pharm Des. 2012;18(21):3119–3146.
doi:10.2174/138161212800672674Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103–e120.
doi:10.1093/cid/ciq257